First Lyme Vaccine in Decades Nears Approval

 Lyme disease remains one of the most common vector-borne infectious diseases in the Northern Hemisphere and its prevalence continues to increase. In the US, approximately 476,000 cases are diagnosed and treated each year, while Europe reported more than 130,000 annual cases.

Despite the substantial disease burden, no vaccine has been approved for human use. That may soon change.

In a press release, Pfizer and Valneva announced positive results from the phase 3 VALOR trial of their VLA15 Lyme disease vaccine.

Researchers evaluated the Lyme disease vaccine candidate PF-07307405 (LB6V, formerly VLA15) in the phase 3 VALOR trial, a randomized, placebo-controlled, blinded study conducted in endemic regions across the US, Canada, and Europe. According to ClinicalTrials.gov, the NCT05477524 trial enrolled approximately 9400 participants aged 5 years or older.

The vaccination schedule included four doses: a primary series administered at months 0, 2, and 5-9, followed by a booster dose 1 year later, given immediately before the next tick season.

The results showed clinically encouraging protection. During the second tick season after completion of the primary immunization series, the incidence of confirmed Lyme disease cases was significantly lower in the vaccine group than in the placebo group. Vaccine efficacy reached 73.2% from day 28 after the fourth dose (95% CI, 15.8%-93.5%).

Researchers have noted that fewer Lyme disease cases occurred during the trial than initially expected. A predefined primary statistical endpoint was not formally met in the first analysis. However, this criterion was achieved in a second prespecified analysis. Despite these methodological limitations, researchers have described the findings as clinically relevant.

Safety Profile

The vaccine candidate showed favorable tolerability in the VALOR study, and no safety signals were found at the time of analysis. Efficacy and safety data will guide the next steps. Based on the available findings, manufacturers plan to submit marketing authorization applications to regulatory agencies. If approved, this vaccine could become the first Lyme disease vaccine available for human use.

Mechanism of Action

The vaccine targets the outer surface protein A (OspA) of Borrelia burgdorferi. This vaccine covers six different serotypes that are epidemiologically relevant across North America and Europe.

After immunization, the body produces antibodies against OspA. When a tick feeds on the blood, these antibodies enter the tick’s gut and bind to Borrelia bacteria, blocking transmission to the human host. This vector-targeted approach differs from traditional vaccines, which primarily stimulate immune responses within the human body.

A Lyme disease vaccine, LYMErix, was approved in the US in the late 1990s. Although it showed good efficacy, it was withdrawn from the market in 2002 because of low demand, safety concerns despite limited supporting evidence, and negative public perception.

The clinical importance of an effective vaccine reflects the often nonspecific and variable presentation of Lyme disease. Early signs, such as erythema migrans or nonspecific general symptoms, are often overlooked or misinterpreted. Untreated infection can spread systemically and lead to complications, including Lyme arthritis, cardiac involvement, and neurologic manifestations. An effective vaccine could shift the focus from delayed diagnosis and treatment toward prevention. Such a change could substantially reduce the disease burden and long-term morbidity.

Vaccination may be particularly important for individuals with greater exposure to ticks, including outdoor workers and travelers to endemic regions. Researchers also expect a decline in chronic disease burden over time.

The VALOR trial findings provide robust evidence supporting the efficacy and safety of this new candidate vaccine for Lyme disease. Despite methodological limitations due to the small number of cases, the data suggest significant preventive potential.

If approved, the vaccine could reshape prevention strategies for one of the most common infectious diseases in Europe and North America, with important implications for clinical practice.

https://www.medscape.com/viewarticle/first-lyme-vaccine-decades-nears-approval-2026a1000f7r